在患有格拉姆阴性细菌感染的儿科患者中使用美罗烯姆/瓦博巴克坦组合的剂量推理
Chiara Fornari1, Antonio Arrieta2, John S Bradley3,4
1Clinical Pharmacology, Pharmacometrics and Clinical DMPK Department, Stemline Therapeutics/Menarini Group, Pomezia, Italy.
British journal of clinical pharmacology
|June 26, 2024
概括
这项研究确定了儿童最佳的美罗烯姆/瓦博巴克坦剂量,并建议婴儿和老年儿童使用特定的治疗方案,以确保有效治疗阴性感染.
科学领域:
- 药理学 药理学是指药理学的学科.
- 儿童传染病 儿童传染病
- 药理动力学 药理动力学
背景情况:
- 梅罗佩内姆/瓦博巴克坦已被批准用于成年人复杂的尿路感染.
- 关于儿科药理动力学和剂量的数据有限.
研究的目的:
- 描述儿科患者的美罗烯姆/瓦博巴克坦的药理动力学.
- 使用基于模型的方法为儿童建立基于证据的剂量方案.
主要方法:
- 对成人和儿科数据 (414名成年人,39名儿童) 的种群药动力学分析.
- 使用成人药理动力学模型为儿科参数估计提供信息.
- 模拟以确定剂量方案,以达到目标的适当概率 (PTA).
主要成果:
- 使用双隔间模型建模了美罗烯姆/瓦博巴克坦的配置.
- 体重和肌素清除值是显著的共同变量.
- 建议的3.5小时IV输注量为40mg/kgQ8h,适用于3个月以上的儿童,20mg/kg适用于新生儿/婴儿<3个月.
结论:
- 综合成人和儿科数据准确地描述了儿童的美罗烯姆/瓦博巴克坦药理动力学.
- 提供了新生儿,婴儿和老年儿童的剂量建议.
- 促进儿童群体安全有效地使用美罗烯姆/瓦博巴克坦.
相关概念视频
Combined Effects of Drugs: Synergism
3.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.8K
Pneumonia IV: Management
318
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
318
Antibiotic Selection
53.0K
Overview
53.0K
Surface Membrane Barriers
1.1K
The skin and mucous membranes serve as the primary line of defense against pathogens by providing both physical and chemical protection. These barriers are essential in preventing the entry and establishment of microbes, thereby maintaining the integrity of the host.
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...
1.1K
Defense Against Bacterial Pathogens
1.4K
The human immune system is a complex network of cells, tissues, and organs that work together to defend the body against bacterial infections. It consists of various immune cells, each playing a specific role in the defense mechanism.
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
1.4K


